Showing results (101-110 of 171) with videos related to

Sort By:
Pageof 18
Plos One|April 7, 2018
Genetic modulation of atrial fibrillation risk in a Hispanic/Latino cohortBrandon Chalazan, Denise Mol, Arvind Sridhar, et al.
Heart Rhythm|August 4, 2009
ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodelingHiroshi Watanabe, Daniel W Kaiser, Seiko Makino, et al.
The Journal of Invasive Cardiology|November 3, 2012
Learning curve in transradial cardiac catheterization: procedure-related parameters stratified by operators' transradial volumeEhab S Kasasbeh, Babar Parvez, Robert L Huang, et al.
Nature Genetics|March 8, 2011
A rare variant in MYH6 is associated with high risk of sick sinus syndromeHilma Holm, Daniel F Gudbjartsson, Patrick Sulem, et al.
Plos One|August 25, 2017
Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillationDaniela Husser, Laura Ueberham, Gerhard Hindricks, et al.
Circulation. Arrhythmia and Electrophysiology|July 14, 2020
Ion Channel and Structural Remodeling in Obesity-Mediated Atrial FibrillationMark D McCauley, Liang Hong, Arvind Sridhar, et al.
JAMA Network Open|January 16, 2019
Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic GroupsZain Alzahrani, Aylin Ornelas-Loredo, Sara D Darbar, et al.
The New England Journal of Medicine|July 11, 2008
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillationDenice M Hodgson-Zingman, Margaret L Karst, Leonid V Zingman, et al.
JAMA Cardiology|November 28, 2019
Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic DrugsAylin Ornelas-Loredo, Shinwan Kany, Vihas Abraham, et al.
The American Journal of Cardiology|January 31, 2015
The AFFORD clinical decision aid to identify emergency department patients with atrial fibrillation at low risk for 30-day adverse eventsTyler W Barrett, Alan B Storrow, Cathy A Jenkins, et al.
Pageof 18